EichorEICHOR
Condition: Relapsed Small Lymphocytic Lymphoma Synced from ClinicalTrials.gov · August 08, 2026

Recruiting studies: Relapsed Small Lymphocytic Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
Phase 2 · 3 location(s) · Massachusetts General Hospital · NCT04560322CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies
Phase 1 · 1 location(s) · Mayo Clinic · NCT04892277Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Phase 1 · 9 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT06980116Q702 for the Treatment of Patients With Hematologic Malignancies
Phase 1 · 2 location(s) · Mayo Clinic · NCT06712810Phase Ib Clinical Study of Keynatinib
Phase 1 · 4 location(s) · Medolution Ltd. · NCT04807881A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
Phase 3 · 2 location(s) · Dizal Pharmaceuticals · NCT07139873Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refracto
Phase 1 · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT04223765Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia o
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT04941716Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r
Phase 1 · 23 location(s) · Imugene Limited · NCT03666000ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Phase 3 · 5 location(s) · Newave Pharmaceutical Inc · NCT07342478A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R)
Phase 3 · 59 location(s) · Merck Sharp & Dohme LLC · NCT05947851A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compar
Phase 3 · 192 location(s) · BeOne Medicines · NCT06943872Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Rel
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT068590083'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic L
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT06839053A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Phase 1 · 62 location(s) · Nurix Therapeutics, Inc. · NCT05131022Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Phase 1/Phase 2 · 11 location(s) · Vironexis Biotherapeutics Inc. · NCT06533579Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
Phase 2 · 11 location(s) · Ascentage Pharma Group Inc. · NCT05147467A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Phase 1 · 6 location(s) · Ascentage Pharma Group Inc. · NCT07424833A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisoca
Phase N/A · 1 location(s) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · NCT06788639A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
Phase 1 · 5 location(s) · Lomond Therapeutics Holdings, Inc. · NCT06708897DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)
Phase 2 · 17 location(s) · Dizal Pharmaceuticals · NCT06539182Allo HSCT Using RIC and PTCy for Hematological Diseases
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT05805605Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small
Phase 1 · 1 location(s) · Paolo Caimi, MD · NCT06916767A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
Phase 1/Phase 2 · 7 location(s) · CRISPR Therapeutics AG · NCT05643742Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed o
Phase 1 · 1 location(s) · University Health Network, Toronto · NCT05963217Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
Phase 1/Phase 2 · 1 location(s) · Medical University of South Carolina · NCT05702853Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small L
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT07194980A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymp
Phase 2 · 35 location(s) · Nurix Therapeutics, Inc. · NCT07221500A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphom
Phase 2 · 31 location(s) · AbbVie · NCT02966756
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.